Literature DB >> 389601

Drug-induced renal disease.

J R Curtis.   

Abstract

The clinical manifestations of drug-induced renal disease may include all the manifestations attributed to natural or spontaneous renal diseases such as acute renal failure, chronic renal failure, acute nephritic syndrome, renal colic, haematuria, selective tubular defects, obstructive nephropathy, etc. It is therefore vital in any patient with renal disease whatever the clinical manifestations might be, to obtain a meticulous drug and toxin inventory. Withdrawal of the offending drug may result in amelioration or cure of the renal disorder although in the case of severe renal failure it may be necessary to utilise haemodialysis or peritoneal dialysis to tide the patient over the period of acute renal failure. Analgesic nephropathy is an important cause of terminal chronic renal failure and it is therefore vital to make the diagnosis as early as possible. The pathogenesis of some drug-induced renal disorders appears to be immunologically mediated. There are many other pathogenetic mechanisms involved in drug-induced renal disorders and some drugs may under appropriate circumstances be responsible for a variety of different nephrotoxic effects. For example, the sulphonamides have been incriminated in examples of crystalluria, acute interstitial nephritis, acute tubular necrosis, generalised hypersensitivity reactions, polyarteritis nodosa and drug-induced lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389601     DOI: 10.2165/00003495-197918050-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  51 in total

1.  Silicon nephropathy.

Authors:  L F Saldanha; V J Rosen; H C Gonick
Journal:  Am J Med       Date:  1975-07       Impact factor: 4.965

2.  St Anthony's fire and pseudochronic renal failure.

Authors:  C D Pusey; D J Rainford
Journal:  Br Med J       Date:  1977-10-08

3.  Renal parenchymal accumulation of aminoglycoside antibiotics in rats.

Authors:  F C Luft; S A Kleit
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

4.  Use of co-trimoxazole in chronic renal failure.

Authors:  P R Tasker; G A MacGregor; H E de Wardener
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

5.  Co-trimoxazole and creatinine clearance.

Authors: 
Journal:  Lancet       Date:  1978-04-01       Impact factor: 79.321

6.  Retroperitoneal fibrosis during treatment with methydopa.

Authors:  B M Iversen; J W Johannesen; E Nordahl; J Ofstad; S Thunold; Y Willassen
Journal:  Lancet       Date:  1975-08-16       Impact factor: 79.321

7.  Pathogenesis and renal function in acute toxic nephropathies.

Authors:  F C Reubi
Journal:  Contrib Nephrol       Date:  1978       Impact factor: 1.580

8.  Analgesic nephropathy. Clinical course after withdrawal of phenacetin.

Authors:  D Bell; D N Kerr; J Swinney; W K Yeates
Journal:  Br Med J       Date:  1969-08-16

9.  Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.

Authors:  C Christiansen; P Rødbro; M S Christensen; B Hartnack; I Transbøl
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

10.  Doxorubicin hydrochloride-associated renal failure.

Authors:  J F Burke; J F Laucius; H S Brodovsky; R Z Soriano
Journal:  Arch Intern Med       Date:  1977-03
View more
  3 in total

Review 1.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 2.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Drug-induced bladder and urinary disorders. Incidence, prevention and management.

Authors:  M J Drake; P M Nixon; J P Crew
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.